Nesiritide in Hypertension

Exclusion Criteria

• •Congestive Heart Failure (any New York Heart Association class)
• •Ejection Fraction ≤ 40 %
• •Known, not appropriately treated, secondary hypertension
• •Myocardial infarction within 3 months of screening
• •Unstable angina within 14 days of screening, or any evidence of myocardial ischemia
• •Pulmonary hypertension
• •Aortic stenosis with maximum jet velocity \> 2,5 m/s
• •Other valvular stenosis, hypertrophic, restrictive or obstructive cardiomyopathy, constrictive pericarditis or biopsy proven active myocarditis
• •Sustained Ventricular Tachycardia or Ventricular Fibrillation within 14 days of screening
• •Sustained Atrial Fibrillation
• •Second or third degree atrioventricular block without a permanent cardiac pacemaker
• •Cerebrovascular event within 3 months of screening, or other evidence of significantly compromised cerebral perfusion
• •Proteinuria defined as albumin:creatinine ratio \> 100 (equivalent to an excretion of \> 1 g/day)
• •Nephrotic syndrome
• •Body Mass Index \> 35
• •Total bilirubin of \> 25 µmol/L, aspartate aminotransferase or alanine aminotransferase 1.5 times the upper limit of normal range
• •Renal insufficiency assessed by estimated glomerular filtration rate (GFR) \< 30 ml/min
• •Serum sodium of ≤ 135 mmol/L and ≥ 150 mmol/L
• •Serum potassium of ≤ 3.5 mmol/L and ≥ 5.5 mmol/L
• •Women taking hormonal contraceptives containing estrogens
• •Pregnancy
• •Patients on prolonged, i.e. more than 30 days, immunosuppressant therapy
• •Patients with known, active malignancies
• •Patients with orthostatic hypotension
• •Participation in a trial with an investigational product within the previous three months
• •Any contraindication listed on the Investigator's Brochure of the Investigational Medicinal Product
• •Any reason why, in the opinion of the investigator, the patient should not participate.